- ≥99% by HPLC per component; lot-matched COA available
- Lot-matched certificate of analysis
- Ships next business day, tracked
CJC-1295 (No DAC) + GHRP-6
Mod GRF (1-29) paired with the first-generation hexapeptide secretagogue GHRP-6
- FormCo-lyophilized powder, sealed glass vial
- Mol. weightCJC-1295 (No DAC): 3367.93 g/mol · GHRP-6: 873.01 g/mol
- Research areasPulsatile GH release, orexigenic and feeding-behaviour models, GHS-receptor pharmacology, cardiac tissue models
Supplied for laboratory research use only. Not for human or veterinary use, and not intended to diagnose, treat, cure or prevent any disease.
Overview
This blend combines CJC-1295 without DAC — the DPP-4-resistant 29-residue GHRH analogue also catalogued as Modified GRF (1-29) — with GHRP-6, the hexapeptide that founded the entire growth hormone-releasing peptide class. GHRP-6 was derived in the 1980s from met-enkephalin analogues, years before ghrelin itself was identified, and its characterisation is what led researchers to the receptor now known as the growth hormone secretagogue receptor. Ghrelin was subsequently discovered as its endogenous ligand.
GHRP-6 is not a selective compound, and that is precisely why it remains in use. Alongside growth hormone release it produces a pronounced appetite response through central ghrelin-receptor activation, and it has measurable effects on cortisol and prolactin at higher exposures. Researchers studying feeding behaviour, orexigenic signalling or the broader pharmacology of the receptor often prefer it over the cleaner second-generation peptides for exactly that reason.
Specifications
Identity
- CAS number
- CJC-1295 (No DAC): 863288-34-0 · GHRP-6: 87616-84-0
- Molecular formula
- CJC-1295 (No DAC): C152H252N44O42 · GHRP-6: C46H56N12O6
- Molecular weight
- CJC-1295 (No DAC): 3367.93 g/mol · GHRP-6: 873.01 g/mol
- Peptide class
- GHRH analogue combined with a first-generation growth hormone-releasing hexapeptide
Supply & purity
- Form
- Co-lyophilized powder, sealed glass vial
- Purity
- ≥99% by HPLC per component; lot-matched COA available
- Available sizes
- 10 mg (5 mg/5 mg)
- Solubility
- Bacteriostatic water
Additional detail
- Blend ratio
- 1:1 CJC-1295 (No DAC) to GHRP-6
- CJC-1295 sequence
- Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2
- GHRP-6 sequence
- His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
- Research areas
- Pulsatile GH release, orexigenic and feeding-behaviour models, GHS-receptor pharmacology, cardiac tissue models
- Storage
- Lyophilized: −20 °C, protected from light and moisture. Reconstituted: 2–8 °C, use within the study window.
Questions about CJC-1295 (No DAC) + GHRP-6
How does GHRP-6 differ from GHRP-2 and Ipamorelin?
All three act at the growth hormone secretagogue receptor but differ in selectivity. GHRP-6 is the original and least selective, with strong appetite stimulation and measurable cortisol and prolactin effects. GHRP-2 is more potent with less appetite response, and Ipamorelin is the most selective of the three.
What is CJC-1295 (No DAC)?
It is a 29-residue GHRH analogue with four amino-acid substitutions that resist DPP-4 cleavage, commonly catalogued as Modified GRF (1-29). Without the Drug Affinity Complex group it does not bind albumin, so it acts briefly and produces a discrete pulse rather than sustained elevation.
Is each component tested separately?
Yes. Purity is confirmed by HPLC and identity by mass spectrometry for each peptide at an independent laboratory before co-lyophilization. The certificate of analysis is matched to the lot number on your vial and available on request at any point.
How should the vial be stored?
Keep the sealed lyophilized vial at −20 °C, protected from light and moisture, where it remains stable long-term. Once reconstituted, hold it at 2–8 °C and use within your study window, avoiding repeated freeze–thaw cycles and prolonged periods at room temperature.
Related
